Radiofrequency catheter ablation-induced gastroparesis successfully treated with administration of mosapride citrate: two case reports

Clin J Gastroenterol. 2020 Apr;13(2):182-185. doi: 10.1007/s12328-019-01038-x. Epub 2019 Aug 27.

Abstract

Atrial fibrillation (AF) is the most common cardiac arrhythmia, and radiofrequency catheter ablation (RFCA) for pulmonary vein isolation is a well-established therapeutic modality for AF. Transient gastroparesis rarely complicates RFCA. We report two cases of RFCA-induced transient gastroparesis, effectively treated with mosapride citrate administration. Case 1. Computed tomography (CT) performed 4 days after RFCA revealed marked gastric dilatation without any gastric or intestinal obstruction. The patient was fasting and was administered mosapride citrate (5 mg thrice a day). The patient's symptoms improved 6 days later, and CT revealed no gastric dilatation. Esophagogastroduodenoscopy revealed gastric peristalsis without residual food in the stomach. Case 2. CT performed 8 days after RFCA revealed marked gastric dilatation without any gastric or intestinal obstruction. The patient was fasting and was administered pantothenic acid (500 mg/day intravenously for 7 days). However, symptoms persisted, and CT revealed residual food in the stomach. The patient was subsequently administered mosapride citrate (5 mg thrice a day). The patient's symptoms improved 4 days later, and contrast-enhanced gastric X-ray using amidotrizoate meglumine revealed gastric peristalsis, passage of amidotrizoate meglumine into the duodenum, and no gastric dilatation. Mosapride citrate is useful to treat RFCA-induced gastroparesis.

Keywords: Ablation; Atrial fibrillation; Gastroparesis; Mosapride citrate.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Benzamides / therapeutic use*
  • Catheter Ablation / adverse effects*
  • Gastrointestinal Agents / therapeutic use*
  • Gastroparesis / drug therapy*
  • Gastroparesis / etiology*
  • Humans
  • Male
  • Middle Aged
  • Morpholines / therapeutic use*
  • Remission Induction

Substances

  • Benzamides
  • Gastrointestinal Agents
  • Morpholines
  • mosapride